Antibody Purification Services Market Trends

Growth Drivers

• Increasing Requirement for DigitalTherapeutics - Digital therapeutics (DTx) represent a novel therapeutic approach grounded on digital technology. As such, there is a marked demand for the clinical use and commercialization of DTx, as well as for its expansion into other clinical sectors. Nevertheless, there is still uncertainty around the use of DTx as a general medicinal component. This uncertainty may stem from a lack of agreement on a definition as well as deficiencies in clinical studies, R&D, regulatory framework standardization, and technological maturity. Patients are more empowered than ever because of the shift to digital healthcare. Because of this, digital health solutions are now essential to coping with the growing number of empowered patients who are making their own treatment decisions.
• Increase in Externalization of Antibody Manufacturing and Purification Services - Numerous firms have several therapeutic monoclonal antibodies (mAbs) in their pipelines, and hundreds are presently under research. This review covers the current approach employed in these compounds' recovery operations. A survey is conducted on fundamental unit activities, including harvest, Protein A affinity chromatography, and extra polishing procedures. There is a discussion of substitute procedures including flocculation, precipitation, and membrane chromatography. The mAb product demand grew quickly, which led to simultaneous measures to boost production capacity by building sizable bulk manufacturing facilities and enhancing cell culture procedures to increase product titers. In addition to improvements in traditional purifying technologies, this combination has resulted in an excess of manufacturing capacity and promises almost infinite production capacity shortly.
• Growth of Contract Production Companies - In response to the COVID-19 pandemic, the creation of mRNA vaccines and their subsequent global manufacturing marks a significant advancement in the production of antibodies. There are about 220 mRNA candidates under research at the moment, and nucleotide-based treatments and vaccinations should see faster growth. The pandemic has concentrated CDMO efforts on quickly scaling up production for commercial supply, but as a result of this new generation of molecules, there is an increasing need for technology and outsourced early-phase development services.

Challenges

• Higher Cost of Antibody Purification Services - Depending on the kind and procedure utilized in the production process, the price of producing an antibody can change. Gene synthesis, recombinant expression, antigens, purification, and protein expression services should all be included in the package's pricing. Most manufacturers and laboratories that specialize in creating custom antibody services estimate that the cost will be approximately USD 899. The typical cost of producing a monoclonal antibody might range from USD 6000 to USD 15000 due to its complexity and increased expense. The process of creating an antibody has been made easier by technological developments, and large-scale antibody production is now feasible. For the most part, biochemical researchers have been quite concerned about custom antibody manufacturing. However, most individuals don't realize how expensive the entire procedure is, so they would rather purchase an antibody that has already been made for use in research, medicine, and vaccine development.

• Lack of Knowledge in People

• Lack of Infrastructure in Growing Countries